UEGW 2021 | Page 2 | Pfizer Medical Information - Gulf Countries (UAE, Oman, Bahrain, Qatar, Kuwait)

Congress Materials

Medical Information

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait

Select I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait

I am a patient / caregiverNo, go back to the patient portal

Select I am a patient / caregiverNo, go back to the patient portal

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.

Back to Congresses

Oral Presentation

Sandborn WJ, D’Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Guo X, Mundayat R, Su C, Panés J October 5, 2021 UEGW 2021 Ulcerative Colitis

Tofacitinib for the treatment of ulcerative colitis: up to 7.8 years of safety data from global clinical trials

View Presentation

Oral Presentation

Rubin DT, Modesto I, Vermeire S, Danese S, Ng SC, Kwok KK, Koram N, Jones TV October 5, 2021 UEGW 2021 Ulcerative Colitis

Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis

View Presentation